Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic stage IV/clinical group IV rhabdomyosarcoma, undifferentiated sarcoma, or ectomesenchymoma~  * No metastatic embryonal tumors in patients under 10 years of age, regardless of primary site~ * Metastatic tumors of parameningeal sites eligible~* Bidimensionally measurable disease~* No positive cerebrospinal fluid cytology or multiple intracranial metastases~* Patients presenting with the following are only eligible for continuation therapy and may not receive irinotecan/vincristine upfront window therapy:~  * Evidence of base of skull erosion or skull metastatic disease that displaces or indents the dura, compresses the brain parenchyma, or causes evidence of cranial nerve palsy~ * Tumor that touches or displaces the spinal cord~ * Evidence of intracranial primary tumor extension~ * Tumors that could cause potentially life-threatening complications (e.g., renal, airway) with progression due to location and/or growth rate~ * Requires emergency radiotherapy~ * Lab values are consistent with disseminated intravascular coagulation~PATIENT CHARACTERISTICS:~Age:~* Under 50 (alveolar rhabdomyosarcoma, undifferentiated sarcoma, and ectomesenchymoma patients)~* 10 to 49 (embryonal histology patients)~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~* Absolute neutrophil count greater than 1,000/mm\^3\*~* Platelet count greater than 150,000/mm\^3\* NOTE: \*Unless there is tumor involvement of bone marrow~Hepatic:~* Bilirubin less than 1.5 mg/dL~* PT, PTT, and fibrinogen less than 1.5 times upper limit of normal~Renal:~* Creatinine less than 1.2 mg/dL~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Prior steroids allowed~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy~Surgery:~* No more than 42 days since prior initial surgical procedure, including biopsy for diagnosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 49 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).